Blurbs

Analysts Conflicted on These Healthcare Names: Graphite Bio (GRPH), Verrica Pharmaceuticals (VRCA) and CSL (OtherCMXHF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Graphite Bio (GRPHResearch Report), Verrica Pharmaceuticals (VRCAResearch Report) and CSL (CMXHFResearch Report).

Graphite Bio (GRPH)

In a report issued on August 11, Luca Issi from RBC Capital maintained a Hold rating on Graphite Bio, with a price target of $11.00. The company’s shares closed last Wednesday at $4.16, close to its 52-week low of $2.07.

According to TipRanks.com, Issi is a 1-star analyst with an average return of -5.0% and a 47.4% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, BioMarin Pharmaceutical, and Adverum Biotechnologies.

Currently, the analyst consensus on Graphite Bio is a Moderate Buy with an average price target of $13.00.

See Insiders’ Hot Stocks on TipRanks >>

Verrica Pharmaceuticals (VRCA)

RBC Capital analyst Gregory Renza maintained a Hold rating on Verrica Pharmaceuticals on August 11 and set a price target of $4.00. The company’s shares closed last Wednesday at $3.69, close to its 52-week low of $1.77.

According to TipRanks.com, Renza is a 4-star analyst with an average return of 5.3% and a 44.4% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Pacira Pharmaceuticals.

Verrica Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $9.67, implying a 155.8% upside from current levels. In a report issued on August 11, Needham also maintained a Hold rating on the stock.

CSL (CMXHF)

In a report released yesterday, Ord Minnett from Ord Minnett maintained a Buy rating on CSL, with a price target of A$330.00. The company’s shares closed last Wednesday at $199.53.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CSL with a $228.15 average price target, which is a 14.3% upside from current levels. In a report issued on August 2, CLSA also maintained a Buy rating on the stock with a A$332.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on GRPH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More